{"created":"2023-06-20T15:47:24.720344+00:00","id":1948,"links":{},"metadata":{"_buckets":{"deposit":"b9970ea5-748f-46b9-9951-b421406e7483"},"_deposit":{"created_by":4,"id":"1948","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"1948"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00001948","sets":["1:11"]},"author_link":["4940"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1985-06-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"896","bibliographicPageStart":"888","bibliographicVolumeNumber":"37","bibliographic_titles":[{"bibliographic_title":"日本産科婦人科學會雜誌","bibliographic_titleLang":"ja"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"卵巣悪性腫瘍に対してCDDPを主体としたcombination chemotherapyを施行し,CDDPのdose-limitingfactorとされている腎障害を可逆的障害のうちに早期に発見予知するため,CDDPの障害部位である腎尿細管に存在する各種酵素,すなわち,LDH,γ-GTP,ALP,AAおよび尿中β_2-microglobulinを測定し,これらのパラメーターにより腎障害の程度が判定できるかどうか,また,血中BUN,Cr,Ccr値測定による腎障害判定よりも有用性が認められるかどうか検討した.1)CDDP点滴静注後の尿中酵素活性の変動は,尿中LDH活性/尿中Cr値(U-LDH/U-Cr),U-γGTP/U-Cr,U-ALP/U-CrおよびU-AA/U-Crは,投与後が投与前に比較して,それぞれ,平均7.2倍,6・0倍,6・4倍および10.4倍の高値を示し,いずれも1週間以内に正常値に回復した.2)CDDP投与後の尿中に排泄されたALP活性はPAGEにより,血清由来ALPではなく腎組織由来ALPであることが判明し,CDDPによる腎尿細管細胞の破壊を間接的に証明した.3)家兎による実験で,CDDP投与時の腎障害予防におけるhydrationの重要性が確かめられた.4)U-AA/U-Cr値と尿中β_2-microglobulin値はよく相関した(相関係数r=0.823).5)血中BUN,Cr,Ccr値が全く正常であっても,U-AA/U-Cr値が正常に回復しない状態でCDDPを使用すると腎障害が出現する.したがって,PAC療法後U-AA/U-Cr値が3週間以上高値を持続している場合はCDDPの使用は禁忌であり,休薬するか他の抗癌剤に切り換えるべきである.以上より,血中BUN,Cr,Ccr値測定よりもU-AA/U-Cr値の連続測定はCDDPによる腎障害の早期発見予知に有用な検査法である.","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本産科婦人科学会","subitem_publisher_language":"ja"}]},"item_3_relation_22":{"attribute_name":"NII論文ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"110002232450","subitem_relation_type_select":"NAID"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 日本産科婦人科学会","subitem_rights_language":"ja"},{"subitem_rights":"本文データは学協会の許諾に基づきCiNiiから複製したものである","subitem_rights_language":"ja"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03009165","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小林, 浩","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"4940","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"sankafujinka-37_6-888.pdf","filesize":[{"value":"762.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"sankafujinka-37_6-888.pdf","url":"https://hama-med.repo.nii.ac.jp/record/1948/files/sankafujinka-37_6-888.pdf"},"version_id":"24a67639-5f92-4725-ae1f-68c01cd0e1f3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Aminopeptidase (Arylamidase)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cisplatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nephrotoxicity","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ovarian carcinoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"卵巣癌とCisplatin : Cisplatinによる腎障害の早期発見法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"卵巣癌とCisplatin : Cisplatinによる腎障害の早期発見法","subitem_title_language":"ja"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"1948","relation_version_is_last":true,"title":["卵巣癌とCisplatin : Cisplatinによる腎障害の早期発見法"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-08-02T07:20:29.694709+00:00"}